PP
AKBA icon

PDS Planning’s Akebia Therapeutics AKBA Stock Holding History

PDS Planning’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57K Hold
50,000
– – ﹤0.01% 605
2026
Q1 		$69.5K Hold
50,000
– – ﹤0.01% 553
2025
Q4 		$80.5K Hold
50,000
– – 0.01% 543
2025
Q3 		$137K Hold
50,000
– – 0.01% 522
2025
Q2 		$182K Buy
50,000
+5,000
+11% +$13.7K 0.01% 489
2025
Q1 		$86.4K Buy
45,000
+30,000
+200% +$61.2K 0.01% 458
2024
Q4 		$28.5K Buy
+15,000
New +$26K ﹤0.01% 442

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PDS Planning's AKBA Position: Q2 2026 in Review

PDS Planning held its Akebia Therapeutics (AKBA) position steady in Q2 2026 at 50,000 shares worth $57K. The position accounts for ﹤0.01% of the portfolio, ranked #605.

PDS Planning first reported a position in AKBA in Q4 2024 and has held it in 7 quarters since. The position peaked at $182K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • PDS Planning held 50,000 shares of Akebia Therapeutics worth $57K as of Q2 2026.
  • PDS Planning left its Akebia Therapeutics share count unchanged in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of PDS Planning's portfolio in Q2 2026, its #605 holding.
  • PDS Planning first reported a position in Akebia Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • PDS Planning's Akebia Therapeutics position peaked at $182K in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on PDS Planning's 13F filing for Q2 2026, filed 5 Aug 2026.